A patient may use a low-dose GLP-1 to manage appetite while running AOD 9604 or Tesamorelin to specifically target visceral fat and preserve muscle
Get in touch for a copy of the full report Some of the key insights within this report were only feasible thanks to our innovative HarmonAIze Boost methodology
Brand & Website By Hope Gathers Studio
Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts
Ge X, Zuo Y, Xie J, Li X, Li Y, Thirupathi A, Yu P, Gao G, Zhou C, Chang Y, Shi Z
